阿扎胞苷联合高三尖杉酯碱治疗老年慢性粒-单核细胞白血病的疗效和安全性分析  

Analysis of efficacy and safety of azacytidine combined with homoharringtonine in treatment of chronic myelomonocytic leukemia

作　　者：丰江舟 孙晓星 纪晓娟 葛洪峰 FENG Jiangzhou;SUN Xiaoxing;JI Xiaojuan;GE Hongfeng(Department of Hematology,the Affiliated Bozhou Hospital of Anhui Medical University,Bozhou 236800,China)

机构地区：[1]安徽医科大学附属亳州医院血液内科,安徽省亳州市236800

出　　处：《实用老年医学》2024年第2期145-148,共4页Practical Geriatrics

基　　金：亳州市重点研发计划项目(b22c2023061)。

摘　　要：目的 评估阿扎胞苷联合高三尖杉酯碱治疗老年慢性粒-单核细胞白血病(CMML)的疗效和安全性。方法 纳入2018—2022年于我院确诊的40例老年CMML病人,按随机数表法分为试验组和对照组,每组20例。试验组接受阿扎胞苷联合高三尖杉酯碱治疗,对照组接受阿扎胞苷治疗,比较2组的疗效、安全性以及预后。结果 共36例病人入组,试验组19例,对照组17例。试验组总缓解率(ORR)高于对照组(84.2%比52.9%,P=0.041)。2组病人不良反应发生率比较,差异无统计学意义(P>0.05)。试验组病人中位生存时间为33.8个月,明显高于对照组中位生存时间(21.2个月)(P<0.05)。结论 阿扎胞苷联合高三尖杉酯碱方案治疗老年CMML安全有效。Objective To evaluate the efficacy and safety of azacitidine combined with homoharringtonine in the treatment of chronic myelomonocytic leukemia(CMML) in the elderly.Methods A total of 40 elderly patients with CMML in our hospital from 2018 to 2022 were enrolled in this study.The patients were divided into the experimental group and the control group according to the random number table.The experimental group received azacitidine combined with homoharringtonine,and the control group received azacitidine regimen.The efficacy and safety of the two groups were analyzed and compared.Results Thirty-six patients were enrolled,with 19 cases in the experimental group and 17 cases in the control group.The overall relieve rate(ORR) of the experimental group was higher than that of the control group(82.4% vs 52.9%,P=0.041).The adverse effects showed no statistically significant differences between the two groups(P>0.05).The median survival time of the patients in the experimental group was 33.8 months,compared with 21.2 months in the control group(P<0.05).Conclusions Azacitidine combined with homoharringtonine is safe and effective in the treatment of CMML in the elderly.

关 键 词：慢性粒-单核细胞白血病 老年人 高三尖杉酯碱 阿扎胞苷 

分 类 号：R733.7[医药卫生—肿瘤]